Skip to Content

STARVAC 4 Plus (Canada)

This page contains information on STARVAC 4 Plus for veterinary use.
The information provided typically includes the following:
  • STARVAC 4 Plus Indications
  • Warnings and cautions for STARVAC 4 Plus
  • Direction and dosage information for STARVAC 4 Plus

STARVAC 4 Plus

This treatment applies to the following species:
Manufacturer: Novartis

Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza3-Respiratory Syncytial Virus Vaccine

Modified Live Virus

Active Ingredients

STARVAC® 4 Plus is a freeze-dried preparation of modified live virus (MLV) strains of IBR, BVD (Type I), BVD (Type II), PI3 and BRSV, plus a sterile liquid component used to rehydrate the freeze-dried vaccine. Components of STARVAC® 4 Plus are propagated in established cell lines, combined in the proper ratio, stabilized and desiccated.

STARVAC 4 Plus Indications

STARVAC® 4 Plus contains BVD Type I and BVD Type II and is recommended for the vaccination of healthy cattle, as an aid in the prevention of disease caused by IBR, BVD (Type I), BVD (Type II), PI3 and BRSV viruses.

DOSAGE & ADMINISTRATION:

Aseptically add the accompanying liquid component to the vaccine, agitate until dissolved. Aseptically inject 2 mL either subcutaneously (SC) or intramuscularly (IM) in the neck region.

Immunization against BRSV requires a second dose of STARVAC® BRSV given 14 to 28 days after the first dose.

Annual revaccination is recommended.

Calves vaccinated before weaning should be revaccinated 30 days after weaning when the possible influence of maternal antibodies is decreased.

Precautions

Store at 2°-7°C. Do not freeze. Use the entire contents when first opened. Burn the containers and all unused contents.

Do not sterilize needles and syringes with chemicals because traces of disinfectant may inactivate the vaccine.

CAUTIONS:

In the event of anaphylaxis, administer epinephrine.

Do not use in pregnant cows or in calves nursing pregnant cows. Abortions may result.

For use in animals only.

Warnings

Do not vaccinate within 21 days before slaughter.

DISCUSSION:

Serologic surveys indicate that the IBR, BVD (Type I), BVD (Type II), PI3 and BRSV viruses are widespread in the cattle population. The viruses are considered contributors to the respiratory disease complex and/or reproductive failure in cattle. Multiple infections do occur, and secondary bacterial infections may exacerbate the disease signs.

Disease signs of IBR may include high fever, conjunctivitis, ocular discharge, increased rate of respiration, coughing, severe inflammation of the nasal mucosa with formation of mucoid plaques, loss of appetite and depression. Cattle infected during pregnancy may abort.

BVD manifests itself in many ways making diagnosis difficult. Diarrhea may be one of the lesser signs observed. A transient diarrhea may be unnoticed until more severe signs are observed in the herd. BVD is often obscured or confused with other conditions of the respiratory disease complex. BVD in pregnant animals may cause abortions or malformed and weak calves at birth.

Calves that are infected during pregnancy that are not aborted or malformed could become persistently infected with noncytopathic BVD virus. On exposure to an antigenically similar cytopathic BVD virus, persistently infected calves can develop a disease with erosions in the alimentary tract this is referred to as “Mucosal Disease” and is fatal.

Persistently infected calves tend to have poor growth rates, low survivability and typically die from chronic, ill-thrift, secondary bacterial and viral infections or mucosal disease (MD)1.

Signs of BVD may include combinations of the following; high fever, respiratory signs, ulcerations in the mouth, profuse salivation, diarrhea, dehydration, rough hair coat, abortion, laminitis, and decreased weight gains. Generally morbidity is high and mortality is low; however, complications with other conditions are common and will increase the severity and mortality. A report examining BVD strains from an outbreak in Ontario indicated that the viruses segregated by cross-neutralization into Type I and Type II groups2. Polyclonal antisera from Type I strains had much higher neutralizing titers against Type I strains than against Type II strains, and polyclonal antisera from Type II strains had much higher neutralizing titers against Type II strains than against Type I strains2.

Disease signs caused by PI3 virus generally appear within 14 days after shipment and arrival of calves at their destination. Signs are weakness, depression, watery to mucopurulent nasal discharge, fever, coughing and weight loss. PI3 virus infection allows other pathogens to invade and replicate in weakened respiratory tissues. Bacterial pathogens such as Pasteurella spp. are more easily able to infect and result in pneumonia in conjunction with a PI3 infection.

BRSV infections generally affect weaned calves although susceptible cattle of any age may become infected. BRSV signs follow an incubation of 5 to 7 days and may include fever, cough, nasal discharge, ocular discharge, anorexia, hyperpnea, pulmonary edema, emphysema, and denuding of ciliated epithelium, leading to secondary bacterial pneumonia and associated sequelae. BRSV signs vary in severity but may rapidly progress to a crisis phase. Deaths may follow within 48 hours after the onset of signs of infection. Clinically, BRSV infection may be indistinguishable from other viral infections associated with bovine respiratory disease (BRD) complex.

1 TAYLOR LF, JANZEN ED, ELLIS JA, VAN DEN HURK JV, WARD P. Performance, survival, necropsy, and virological findings from calves persistently infected with the bovine viral diarrhea virus originating from a single Saskatchewan beef herd. Can Vet J 1997; 38: 29-37.

2 CARMAN S, VAN DREUMEL T, RIDPATH J, HAZLETT M, ALVES D, DUBOVI E, TREMBLAY R, BOLIN S, GODKIN A, ANDERSON N. Severe acute bovine viral diarrhea in Ontario, 1993-1995. J Vet Diagn Invest 1998; 10: 27-35.

Manufactured by Diamond Animal Health, Inc., Des Moines, IA

USDA Vet. Biologics Est. Lic. No. 213

For Novartis Animal Health Canada Inc., Mississauga, Ontario, Canada L5N 1V9

1-800-387-6325

® Registered trademark of Novartis AG

Product Code 1041 (10 Doses) 1042 (50 Doses)

02216-2

NAC No.: 12310611

ELANCO CANADA LIMITED
Distributed by ELANCO, Division Eli Lilly Canada Inc. & ELANCO CANADA LIMITED (successor to Novartis Animal Health Canada Inc.)
RESEARCH PARK CENTRE, 150 RESEARCH LANE, SUITE 120, GUELPH, ON, N1G 4T2
Telephone:   519-821-0277
Order Desk:   800-773-7603
Fax:   519-821-7831
Elanco Canada Limited Customer Service Telephone:   800-387-6325
Elanco Canada Limited Customer Service Fax:   800-827-5782
Website:   www.Elanco.ca
Every effort has been made to ensure the accuracy of the STARVAC 4 Plus information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Copyright © 2016 North American Compendiums. Updated: 2016-08-21

Hide